Gemcitabine and Irinotecan as First-Line Therapy for Carcinoma of Unknown Primary: Results of a Multicenter Phase II Trial

Metastatic carcinoma of unknown primary (CUP) has a very poor prognosis, and no standard first-line therapy currently exists. Here, we report the results of a phase II study utilizing a combination of gemcitabine and irinotecan as first-line therapy. Treatment was with gemcitabine 1000 mg/m(2) and i...

Descripción completa

Detalles Bibliográficos
Autores principales: Holtan, Shernan G., Steen, Preston D., Foster, Nathan R., Erlichman, Charles, Medeiros, Fabiola, Ames, Matthew M., Safgren, Stephanie L., Graham, David L., Behrens, Robert J., Goetz, Matthew P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3398897/
https://www.ncbi.nlm.nih.gov/pubmed/22815703
http://dx.doi.org/10.1371/journal.pone.0039285

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3398897/
https://www.ncbi.nlm.nih.gov/pubmed/22815703
http://dx.doi.org/10.1371/journal.pone.0039285

Ejemplares similares